Rhabdomyosarcoma

Raphael L. Yechieli, Henry C. Mandeville, Susan M. Hiniker, Valerie Bernier-Chastagner, Susan McGovern, Giovanni Scarzello, Suzanne Wolden, Alison Cameron, John Breneman, Raquel Davila Fajardo, Sarah S. Donaldson

Research output: Contribution to journalArticlepeer-review

Abstract

Rhabdomyosarcoma is a heterogeneous disease both in presentation and histology. Improvements in a multimodality therapy resulted in the improved overall survival for patients with a low-risk and intermediate-risk disease but not for patients with a metastatic disease. We reviewed and contrasted the North American and European practice patterns, though ultimately the principles of staging, surgery, radiation therapy, and chemotherapy are similar in both Children's Oncology Group and International Society of Paediatric Oncology treatment approaches. Efforts are underway to investigate improved local control rates in higher risk patients using radiation dose escalation strategies, and delayed primary excision in select cases. The prognostic significance of imaging-based chemotherapy response, proton therapy, novel biomarkers, and targeted drugs will be determined in upcoming clinical trials.

Original languageEnglish (US)
Article numbere28254
JournalPediatric Blood and Cancer
Volume68
Issue numberS2
DOIs
StatePublished - May 2021
Externally publishedYes

Keywords

  • chemotherapy
  • Rhabdomyosarcoma
  • surgery radiation oncology

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Rhabdomyosarcoma'. Together they form a unique fingerprint.

Cite this